These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 28192114)

  • 21. Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study.
    Goldberg HJ; Harari S; Cottin V; Rosas IO; Peters E; Biswal S; Cheng Y; Khindri S; Kovarik JM; Ma S; McCormack FX; Henske EP
    Eur Respir J; 2015 Sep; 46(3):783-94. PubMed ID: 26113676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of Progression and Mortality in Lymphangioleiomyomatosis.
    Xu W; Yang C; Cheng C; Wang Y; Hu D; Huang J; He Y; Wang J; Chen K; Yang L; Zhou W; Zhang T; Liu S; Dai J; Meng S; Li X; Yang Y; Wang ST; Feng R; Zhang W; Zhang H; Wang L; Tian X; Xu KF
    Chest; 2023 Jul; 164(1):137-148. PubMed ID: 36801466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum vascular endothelial growth factor-D as a diagnostic and therapeutic biomarker for lymphangioleiomyomatosis.
    Hirose M; Matsumuro A; Arai T; Sugimoto C; Akira M; Kitaichi M; Young LR; McCormack FX; Inoue Y
    PLoS One; 2019; 14(2):e0212776. PubMed ID: 30818375
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Jones AM; Julien-Williams PA; Stylianou M; Moss J
    Chest; 2015 Jan; 147(1):180-187. PubMed ID: 25167325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lymphangioleiomyomatosis treatment with sirolimus.
    Casanova A; María Girón R; Acosta O; Barrón M; Valenzuela C; Ancochea J
    Arch Bronconeumol; 2011 Sep; 47(9):470-2. PubMed ID: 21440356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current management of lymphangioleiomyomatosis.
    Taillé C; Borie R; Crestani B
    Curr Opin Pulm Med; 2011 Sep; 17(5):374-8. PubMed ID: 21760507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concentration of Serum Vascular Endothelial Growth Factor (VEGF-D) and Its Correlation with Functional and Clinical Parameters in Patients with Lymphangioleiomyomatosis from a Brazilian Reference Center.
    Amaral AF; de Oliveira MR; Dias OM; Arimura FE; Freitas CSG; Acencio MMP; de Alvarenga VA; Kairalla RA; Carvalho CRR; Baldi BG;
    Lung; 2019 Apr; 197(2):139-146. PubMed ID: 30623243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA-125 in Disease Progression and Treatment of Lymphangioleiomyomatosis.
    Glasgow CG; Pacheco-Rodriguez G; Steagall WK; Haughey ME; Julien-Williams PA; Stylianou MP; Gochuico BR; Moss J
    Chest; 2018 Feb; 153(2):339-348. PubMed ID: 28576630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus Therapy for Patients With Lymphangioleiomyomatosis Leads to Loss of Chylous Ascites and Circulating LAM Cells.
    Harari S; Elia D; Torre O; Bulgheroni E; Provasi E; Moss J
    Chest; 2016 Aug; 150(2):e29-32. PubMed ID: 27502989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of sirolimus in the treatment of lymphangioleiomyomatosis: favorable responses in patients with different extrapulmonary manifestations.
    Freitas CS; Baldi BG; Araújo MS; Heiden GI; Kairalla RA; Carvalho CR
    J Bras Pneumol; 2015; 41(3):275-80. PubMed ID: 26176526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus for lymphangioleiomyomatosis lesions.
    Egan JJ; Remund KF; Corris P
    N Engl J Med; 2008 May; 358(18):1963-4; author reply 1964. PubMed ID: 18450609
    [No Abstract]   [Full Text] [Related]  

  • 33. The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.
    El-Chemaly S; Henske EP
    Expert Rev Respir Med; 2015 Apr; 9(2):195-204. PubMed ID: 25757365
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
    Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
    Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of serum vascular endothelial growth factor-D concentration with clinical presentation and course of lymphangioleiomyomatosis.
    Radzikowska E; Jaguś P; Sobiecka M; Chorostowska-Wynimko J; Wiatr E; Kuś J; Roszkowski-Śliż K
    Respir Med; 2015 Nov; 109(11):1469-75. PubMed ID: 26386638
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.
    Glasgow CG; Avila NA; Lin JP; Stylianou MP; Moss J
    Chest; 2009 May; 135(5):1293-1300. PubMed ID: 19420197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
    Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
    Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of sirolimus for the prevention of recurrent pneumothorax in patients with lymphangioleiomyomatosis: a case series.
    Zhou L; Ouyang R; Luo H; Ren S; Chen P; Peng Y; Liu T; Liu G
    Orphanet J Rare Dis; 2018 Sep; 13(1):168. PubMed ID: 30241551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-converting enzyme inhibitors may affect pulmonary function in lymphangioleiomyomatosis.
    Steagall WK; Stylianou M; Pacheco-Rodriguez G; Moss J
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus amelioration of clinical symptoms of recurrent lymphangioleiomyomatosis after living-donor lobar lung transplantation.
    Sugimoto R; Nakao A; Yamane M; Toyooka S; Okazaki M; Aoe M; Seyama K; Date H; Oto T; Sano Y
    J Heart Lung Transplant; 2008 Aug; 27(8):921-4. PubMed ID: 18656809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.